Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.41 |
| ▸ | IDH2 | P48735 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.34 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.34 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829461 | 0.80 | HRH4 (0.52) | HRH4IDH2IKBKBEHMT2EHMT1 | |
| SCHEMBL6017006 | 0.78 | HRH4 (0.48) | HRH4IDH2IKBKBEHMT2EHMT1 | |
| SCHEMBL6231272 | 0.75 | KCNH2 (0.43) | KCNH2TLR7 | |
| SCHEMBL27589550 | 0.75 | HRH4 (0.50) | HRH4IDH2IKBKBEHMT2EHMT1 | |
| SCHEMBL10706738 | 0.68 | NUDT1 (0.43) | HRH4 | |
| SCHEMBL1411334 | 0.67 | KCNH2 (0.38) | KCNH2TLR7 | |
| SCHEMBL11576770 | 0.67 | TLR8 (0.41) | KCNH2TLR7 | |
| Cyromazine SCHEMBL27231 | 0.65 | NUDT1 (0.43) | HRH4 | |
| Cyromazine SCHEMBL10832935 | 0.65 | NUDT1 (0.43) | HRH4 | |
| SCHEMBL11482610 | 0.64 | PDE4A (0.56) | HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7265114-B2 | Methods and compositions of novel triazine compounds | REDDY US THERAPEUTICS, INC. (US) | 2007-09-04 | — | — | US | disclosed |
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | DR. REDDY'S LABORATORIES LTD. (IN) | 2006-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060172984-A1 | Methods and compositions of novel triazine compounds | AREG, TGFB1, PTGIS | HRH4 607/4885IDH2 2587/4885HRH3 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.